Altered energy metabolism in cancer: A unique opportunity for therapeutic intervention

Cancer Biology and Therapy

Volumn 14, Issue 2, 2013, Pages 81-89

  Zhang, Yi ^a   Yang, Jin Ming ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Cancer metabolism; Cancer therapy; Cell death; Cell survival

Indexed keywords

GLUTAMINE;

CANCER SURVIVAL; CANCER THERAPY; CELL METABOLISM; ENERGY METABOLISM; EVIDENCE BASED MEDICINE; GLYCOLYSIS; MITOCHONDRION; NEOPLASM; OXIDATIVE PHOSPHORYLATION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR CELL; TUMOR GROWTH;

CANCER METABOLISM; CANCER THERAPY; CELL DEATH; CELL SURVIVAL;

ANTINEOPLASTIC AGENTS; ENERGY METABOLISM; GLUTAMINE; GLYCOLYSIS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MITOCHONDRIA; NEOPLASMS; OXIDATIVE PHOSPHORYLATION;

EID: 84873462831     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22958     Document Type: Review

References (72)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013.
2. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14; PMID:13298683; http://dx.doi.org/10.1126/science.123.3191.309.
3. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2:683-93; PMID:12209157; http://dx.doi.org/10. 1038/nrc882.
4. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011; 27:441-64; PMID:21985671; http://dx.doi.org/10.1146/annurevcellbio-092910-154237.
5. Schornack PA, Gillies RJ. Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia 2003; 5:135-45; PMID:12659686.
6. Smallbone K, Gavaghan DJ, Gatenby RA, Maini PK. The role of acidity in solid tumour growth and invasion. J Theor Biol 2005; 235:476-84; PMID:15935166; http://dx.doi.org/10.1016/j.jtbi.2005.02.001.
7. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11:85-95; PMID:21258394; http://dx.doi.org/10.1038/nrc2981.
8. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997; 80:1046-51; PMID:9305704; http://dx.doi.org/10.1002/ (SICI)1097-0142(19970915)80:6;1046::AIDCNCR6; 3.0.CO;2-7.
9. Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 2002; 93:1123-8; PMID:12417042; http://dx.doi.org/ 10.1111/j.1349-7006.2002.tb01214.x.
10. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 2007; 59:495-505; PMID:16906425; http://dx.doi.org/10.1007/s00280-006-0291-9.
11. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208:313-26; PMID:21242296; http://dx.doi.org/10.1084/jem.20101470.
12. Pedersen PL. Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment's roles together with hexokinase-2 in the "Warburg effect" in cancer. J Bioenerg Biomembr 2008; 40:123-6; PMID:18780167; http://dx.doi.org/10.1007/ s10863-008-9165-7.
13. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001; 173:83-91; PMID:11578813; http://dx.doi.org/10.1016/S0304-3835(01) 00667-X.
14. Bluemlein K, Grüning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011; 2:393-400; PMID:21789790.
15. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011; 334:1278-83; PMID:22052977; http://dx.doi.org/10.1126/science. 1211485.
16. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 2012; 209:217-24; PMID:22271574; http://dx.doi.org/10.1084/jem.20111487.
17. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence and restricted patient survival in human cervical cancers. Cancer Res 2000; 60:916-21; PMID:10706105.
18. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010; 107:2037-42; PMID:20133848; http://dx.doi.org/10.1073/pnas.0914433107.
19. Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS One 2011; 6:e24102; PMID:21949692; http://dx.doi.org/10.1371/ journal.pone.0024102.
20. Bhardwaj V, Rizvi N, Lai MB, Lai JC, Bhushan A. Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. Anticancer Res 2010; 30:743-9; PMID:20392992.
21. El Sayed SM, El-Magd RM, Shishido Y, Chung SP, Diem TH, Sakai T, et al. 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects. J Bioenerg Biomembr 2012; 44:61-79; PMID:22318356; http://dx.doi.org/10.1007/s10863-012-9409-4.
22. Michelakis ED, Webster L, Mackey Jr. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99:989-94; PMID:18766181; http://dx.doi.org/10.1038/sj.bjc.6604554.
23. Kuo W, Lin J, Tang TK. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer 2000; 85:857-64; PMID:10709108; http://dx.doi.org/10.1002/(SICI)1097- 0215(20000315856857AID-IJC2030CO2-U
24. Varshney R, Dwarakanath B, Jain V. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int J Radiat Biol 2005; 81:397-408; PMID:16076755; http://dx.doi.org/10.1080/ 09553000500148590.
25. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 2007; 292:C125-36; PMID:16971499; http://dx.doi.org/10.1152/ajpcell.00247.2006.
26. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26:299-310; PMID:17415526; http://dx.doi.org/10.1007/s10555-007-9064-0.
27. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275:21797-800; PMID:10823814; http://dx.doi.org/10.1074/jbc.C000023200.
28. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64:3892-9; PMID:15172999; http://dx.doi.org/10.1158/0008-5472.CAN-03-2904.
29. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, et al. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006; 25:7225-34; PMID:16715124; http://dx.doi.org/10.1038/sj.onc.1209709.
30. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-12; PMID:18772396; http://dx.doi.org/10.1126/science.1164382.
31. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in highgrade gliomas but not in other solid tumors. Hum Mutat 2009; 30:7-11; PMID:19117336; http://dx.doi.org/10.1002/humu.20937.
32. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324:261-5; PMID:19359588; http://dx.doi.org/10.1126/ science.1170944.
33. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462:739-44; PMID:19935646; http://dx.doi.org/10.1038/nature08617.
34. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. Energy metabolism in tumor cells. FEBS J 2007; 274:1393-418; PMID:17302740; http://dx.doi.org/10.1111/j.1742-4658. 2007.05686.x.
35. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 2006; 175:913-23; PMID:17158952; http://dx.doi.org/10.1083/jcb.200512100.
36. Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol 2010; 30:1303-18; PMID:20100866; http://dx.doi.org/10.1128/MCB.01101-09.
37. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25:460-70; PMID:21317241; http://dx.doi.org/10. 1101/gad.2016311.
38. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, Sotgia F, et al. Stromalepithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol 2011; 43:1045-51; PMID:21300172; http://dx.doi.org/10.1016/j.biocel. 2011.01.023.
39. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010; 9:2412-22; PMID:20562527; http://dx.doi.org/10.4161/cc.9.12.11989.
40. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010; 9:3506-14; PMID:20818174; http://dx.doi.org/10. 4161/cc.9.17.12731.
41. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118:3930-42; PMID:19033663.
42. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011; 10:1271-86; PMID:21512313; http://dx.doi.org/10.4161/cc.10.8.15330.
43. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17:1498-503; PMID:22037646; http://dx.doi.org/10.1038/nm.2492.
44. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, et al. The autophagic tumor stroma model of cancer or "battery-operated tumor growth: A simple solution to the autophagy paradox. Cell Cycle 2010; 9:4297-306; PMID:21051947; http://dx.doi.org/10.4161/cc.9.21. 13817.
45. Riccio A, Del Prato S, Vigili de Kreutzenberg S, Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. Diabete Metab 1991; 17:180-4; PMID:1936473.
46. Deng YT, Huang HC, Lin JK. Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling. Mol Carcinog 2010; 49:141-51; PMID:19777565.
47. Wolvetang EJ, Johnson KL, Krauer K, Ralph SJ, Linnane AW. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett 1994; 339:40-4; PMID:8313978; http://dx.doi.org/10.1016/0014-5793(94)80380-3.
48. Dong LF, Low P, Dyason JC, Wang XF, Prochazka L, Witting PK, et al. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 2008; 27:4324-35; PMID:18372923; http://dx.doi.org/10.1038/onc.2008.69.
49. Xiao D, Powolny AA, Singh SV. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem 2008; 283:30151-63; PMID:18768478; http://dx.doi.org/10.1074/jbc. M802529200.
50. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5:493-506; PMID:16732220; http://dx.doi.org/10.1038/nrd2060.
51. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science 1955; 122:501-14; PMID:13255879; http://dx.doi.org/10.1126/science.122.3168.501.
52. Kovacevic Z, Morris HP. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res 1972; 32:326-33; PMID:4400467.
53. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15:110-21; PMID:22225880; http://dx.doi.org/10.1016/j.cmet.2011.12.009.
54. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010; 35:427-33; PMID:20570523; http://dx.doi.org/10. 1016/j.tibs.2010.05.003.
55. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8:311-21; PMID:16226706; http://dx.doi.org/10.1016/j.ccr.2005.09.008.
56. Carvalho MA, Zecchin KG, Seguin F, Bastos DC, Agostini M, Rangel AL, et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 2008; 123:2557-65; PMID:18770866; http://dx.doi.org/10.1002/ijc.23835.
57. Orita H, Coulter J, Lemmon C, Tully E, Vadlamudi A, Medghalchi SM, et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res 2007; 13:7139-45; PMID:18056164.
58. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104:19345-50; PMID:18032601; http://dx.doi.org/ 10.1073/pnas.0709747104.
59. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007; 178:93-105; PMID:17606868; http://dx.doi.org/10.1083/jcb. 200703099.
60. Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle 2010; 9:3921-32; PMID:20935507; http://dx.doi.org/10.4161/cc.9.19.13139.
61. Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One 2009; 4:e4715; PMID:19262748; http://dx.doi.org/10.1371/journal. pone.0004715.
62. Lessner HE, Valenstein S, Kaplan R, DeSimone P, Yunis A. Phase II study of L-asparaginase in the treatment of pancreatic carcinoma. Cancer Treat Rep 1980; 64:1359-61; PMID:7471124.
63. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67:6745-52; PMID:17638885; http://dx.doi.org/10.1158/0008-5472.CAN-06-4447.
64. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136:521-34; PMID:19203585; http://dx.doi.org/10.1016/j.cell.2008.11.044.
65. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458:762-5; PMID:19219026; http://dx.doi.org/10.1038/nature07823.
66. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18:207-19; PMID:20832749; http://dx.doi.org/10.1016/j.ccr. 2010.08.009.
67. Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem 1984; 259:6215-21; PMID:6144677.
68. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 2008; 10:R84; PMID:18922152; http://dx.doi.org/10.1186/bcr2154.
69. Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, Wise DR, et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med 2011; 52:1947-55; PMID:22095958; http://dx.doi.org/10.2967/jnumed.111.093815.
70. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325:1555-9; PMID:19661383; http://dx.doi.org/10. 1126/science.1174229.
71. Chen V, Staub RE, Fong S, Tagliaferri M, Cohen I, Shtivelman E. Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOS. PLoS One 2012; 7:e30300; PMID:22319564; http://dx.doi.org/10.1371/ journal.pone.0030300.
72. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011; 10:2350-62; PMID:21992792; http://dx.doi.org/10.1158/1535- 7163.MCT-11-0497.